XTalks

AUGUST 13, 2024

Abbott and Medtronic have struck a global partnership to make diabetes management easier for people who need regular insulin injections. Abbott’s CGM sensors will work with Medtronic’s AID algorithms to automatically adjust insulin levels based on real-time blood sugar readings. billion by 2033.

Insulin 52

Insulin FDA Approval Marketing Development 52

XTalks

DECEMBER 11, 2024

In this episode, Ayesha spoke with Jonathan Rigby, MBA, CEO of Sernova , a Canadian biotech company developing innovative cell therapy-based approaches for the management of type 1 diabetes. and IM Therapeutics, which is developing therapies for type 1 diabetes.

Life Science 52

Life Science Clinical Trials Clinical Trials Trials 52

XTalks

APRIL 15, 2025

Individuals with the condition often develop low muscle tone, short stature and intellectual and development issues. One of its most debilitating symptoms is hyperphagia, which significantly impairs quality of life and places patients at constant risk of obesity-related complications. The FDA rejected it in 2022.

FDA Approval 59

FDA Approval Clinical Trials Clinical Trials Trials 59

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Diamyd Medical is a clinical-stage biopharmaceutical company that develops therapies for type 1 diabetes. cells (see video above).

Vaccination 103

Vaccination Vaccine Insulin Trials 103

XTalks

NOVEMBER 23, 2022

Tzield is an immunotherapy that was in development for over three decades. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. It’s the first approved treatment for slowing the progression of stage 2 type 1 diabetes to stage 3, the stage at which a clinical diagnosis is made.

Life Science 52

Life Science FDA Approval Vaccination Vaccine 52

XTalks

FEBRUARY 2, 2023

The US Food and Drug Administration (FDA) has recently cleared for marketing an app called Tidepool Loop which can be used with compatible devices for automated insulin dosing (AID). The Tidepool loop app involves three integral parts: an integrated continuous glucose monitor (iCGM), a controller and an insulin pump.

Insulin 52

Insulin Marketing Life Science Development 52

XTalks

MARCH 17, 2025

Roche, a global leader in biotechnology and diagnostics, has entered into an exclusive collaboration and licensing agreement with Zealand Pharma, a specialist in innovative therapeutics, to co-develop and co-commercialize petrelintide as a potential foundational therapy for people with overweight and obesity. billion $1.4

Hormones 59

Hormones Drugs Sales Insulin 59

XTalks

NOVEMBER 22, 2022

The immunotherapy, which took 36 years to develop, has become the first drug approved to delay the progression of type 1 diabetes. According to experts, delaying the final stages of type 1 diabetes could help prevent patients from years of taking insulin, monitoring blood sugar and watching their diet.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

XTalks

JANUARY 16, 2025

Linsitinib, an oral small molecule that targets the insulin-like growth factor-1 receptor (IGF-1R), is designed to address the underlying mechanisms driving thyroid eye disease. In Tepezzas Phase III study, 10% of patients who received the treatment developed hearing impairment.

Trials 59

Trials Clinical Trials Clinical Trials Insulin 59

XTalks

JANUARY 16, 2023

Type 2 diabetes typically occurs in older adults but the number of children developing the disease is increasing due to rising obesity and inactivity. Often, diabetes medication or insulin therapy are used as management tools. Live and On-Demand: Wednesday, March 22, 2023, at 11am EDT (4pm CET/EU-Central).

Insulin 93

Insulin Regulation Development Drugs 93

XTalks

JUNE 3, 2021

A new Australian study suggests that eating fruit may lead to a reduced risk of developing type 2 diabetes. Researchers at the Edith Cowan University’s (ECU) Institute for Nutrition Research in Perth, Australia found that consuming at least two servings of fruit a day was linked to 36 percent lower odds of developing type 2 diabetes.

Insulin 59

Insulin Development Research Doctors 59

XTalks

JULY 15, 2024

Congenital HI is a genetic disorder that causes excessive insulin production by the pancreas, which lowers plasma or blood sugar. Agonist engagement of the receptor is involved in insulin and glucose regulation, and hence has therapeutic implications for diseases like diabetes and obesity.

Drugs 52

Drugs Insulin Life Science Marketing 52

XTalks

JULY 15, 2024

Congenital HI is a genetic disorder that causes excessive insulin production by the pancreas, which lowers plasma or blood sugar. Agonist engagement of the receptor is involved in insulin and glucose regulation, and hence has therapeutic implications for diseases like diabetes and obesity.

Insulin 52

Insulin Drugs Life Science Marketing 52

Pharmaceutical Technology

JANUARY 31, 2023

The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. It’s much needed. It’s a hot area.” trillion Consolidated Appropriations Act.

Drugs 130

Drugs Gene Therapy Regulation Insulin 130

XTalks

DECEMBER 14, 2022

CGMs can alert diabetics sufficiently in advance of too high or low blood glucose levels, allowing the wearer to improve the situation with insulin, for example. a leader in diabetes care technology, develops small, wearable CGMs that send glucose information to your mobile device (e.g., Dexcom, Inc. , a cellphone) every five minutes.

Insulin 98

Insulin Marketing Branding Life Science 98

XTalks

OCTOBER 22, 2021

In July 2021, the agency approved the first interchangeable biosimilar product, Semglee (insulin glargine-yfgn) for the treatment of diabetes. Semglee is both biosimilar to, and interchangeable with, Lantus (insulin glargine).

FDA Approval 98

FDA Approval Production Insulin Antibody 98

XTalks

NOVEMBER 27, 2024

million) will be dedicated to the production and development of a second-generation Thymoglobulin. billion) insulin manufacturing facility at its Frankfurt Höchst campus in Germany. Sanofi says its Lyon Gerland facility is the exclusive producer of Thymoglobulin, manufacturing around 1.6 And over €15 million ($15.92 billion ($1.38

Production 96

Production Manufacturing Drugs Antibody 96

XTalks

APRIL 29, 2022

These bind to their respective receptors to increase glucose metabolism by increasing insulin secretion. We’re proud to research and develop potentially innovative treatments like tirzepatide, which helped nearly two thirds of participants on the highest dose reduce their body weight by at least 20 percent in SURMOUNT-1,” said Emmick.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

pharmaphorum

MARCH 7, 2022

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. . ” About the author . . ” About the author .

Vaccination 98

Vaccination Vaccine Manufacturing Production 98

Roots Analysis

JANUARY 23, 2024

The peptide therapeutics market has undergone substantial evolution since the inception of insulin. It is noteworthy that peptide is a complex class of drugs that possess many manufacturing challenges, including complex process and big-budget development and manufacturing.

Development 40

Development Contract Manufacturing Drugs Manufacturing 40

XTalks

JULY 17, 2024

Octreotide is a synthetic analog of somatostatin, a hormone in the body that inhibits the release of several other hormones, including growth hormone (GH), glucagon and insulin. Acromegaly develops when the pituitary gland produces excess GH during adulthood.

Hormones 59

Hormones Trials Clinical Trials Clinical Trials 59

XTalks

FEBRUARY 6, 2024

Successful biotech IPOs in 2024 have the potential to generate substantial returns for early investors and provide the crucial capital required for biotech firms to sustain and advance their research and development endeavors. Fractyl Health is actively developing two promising therapies for T2D treatment. per share.

Gene Therapy 98

Gene Therapy Gene Clinical Trials Clinical Trials 98

XTalks

SEPTEMBER 2, 2020

Viking Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapies for metabolic and endocrine disorders. It was developed by Viking Therapeutics for the treatment of lipid and metabolic disorders. Related: Six of the Latest NASH/NAFLD Webinars. NASH may result in severe liver scarring and cirrhosis.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Insulin 98

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. All drug development processes evaluate a drug’s pharmacokinetics (PK) to gather data about its absorption, distribution, metabolism, and excretion in the body.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

XTalks

FEBRUARY 21, 2024

The importance of identifying effective solutions for MASH is evident from the overall interest from the pharmaceutical industry and the competition in developing treatments for this serious liver condition. There are on-going studies to develop formulations with extended duration of action.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

XTalks

FEBRUARY 14, 2024

Allocation of Profits, PBMs Under Fire The CEOs defended high prescription drug prices saying that a big chunk of pharma profits go towards funding the research and development of new medicines. Explain how you justify that division of dividends and stock buybacks versus research and development.

Drugs 52

Drugs Insulin Pharmacy Development 52

XTalks

SEPTEMBER 17, 2020

While the table lists acceptable surrogate endpoints for trials of more common conditions, such as asthma, type 2 diabetes and various cancer types, the document also provides key information to developers of certain rare disease therapies. Prevalence: 1 in 7,000 to 1 in 10,000.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

APRIL 29, 2021

This means that, for clinical trial sponsors, language can no longer be a secondary cost, and must be included in the drug development life cycle. Linguistic validation is a critical tool in the effort to ensure patient diversity and develop a robust understanding of the patient experience across global populations.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Drugs 95

The Pharma Data

JANUARY 5, 2021

Novasep’s chromatography unit comprises resin-based batch and intensified chromatography systems, and primarily focuses on high-pressure, multi-use applications for smaller molecules, such as oligonucleotides, peptides and insulin. In 2019, the company employed approx. 6,200 people, and earned sales revenue of 1,440.6 million euros.

Manufacturing 40

Manufacturing Sales Contract Manufacturing Insulin 40

XTalks

JANUARY 5, 2024

Related: Zepbound, Obesity Version of Eli Lilly’s Mounjaro, Finally Gets FDA Nod So far, LillyDirect provides support for 14 Lilly medicines, with 12 being different formulations and types of insulin. In addition to these and Zepbound, Lilly’s medication for migraine management, Emgality (galcanezumab), is also available through the website.

Drugs 59

Drugs Pharmacy Cosmetics Medicine 59

XTalks

JUNE 12, 2023

These powerhouse organizations have not only distinguished themselves through their cutting-edge devices and technologies but also via their robust research and development (R&D) capabilities, unwavering commitment to quality and extensive global reach. The company reported an investment of $2.7

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

XTalks

JULY 4, 2024

We will also examine the rising stars like Novo Nordisk’s Ozempic (semaglutide), which has become a frontrunner in diabetes management, and the dynamic performance of Gilead Sciences’ Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in the HIV treatment landscape.

Sales 40

Sales Drugs FDA Approval Marketing 40

XTalks

NOVEMBER 21, 2024

These gut hormones are released in response to nutrient intake and play a crucial role in the incretin effect, which enhances insulin secretion. It’s the first and only approved dual agonist targeting both the GIP and GLP-1 receptors.

Sales 106

Sales Insulin Drugs Trials 106

XTalks

FEBRUARY 8, 2021

Last year, Biocon Biologics and Mylan announced they’d be seeking interchangeable status for their long-acting insulin product Semglee , developed to be an alternative to Sanofi’s Lantus (insulin glargine). In a stepwise fashion, the pyramid of evidence is built based on extensive comparisons.”.

Production 78

Production Insulin Branding Generic Drugs 78

Pharmaceutical Technology

DECEMBER 22, 2022

The company has partnered with life sciences-focused investors Sixth Street and Royalty Pharma with an aim to bring substantial non-dilutive, low-cost capital to boost innovation and growth. billion to expedite research and development (R&D) for infectious diseases in lower-income countries.

Insulin 130

Insulin Production Development Genetics 130

Pharmaceutical Technology

FEBRUARY 16, 2023

Despite such a broad range of pathologies, the commonality between them is the insulin response. dietary restriction) of the evolutionarily conserved insulin signalling pathway. Can we extend human life? These experiments demonstrated that the linkage between ageing and insulin was conserved up the evolutionary tree.

Insulin 130

Insulin DNA Genetics Life Science 130

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. Jardiance (Empagliflozin) Jardiance sales in 2022: $8.388 billion Company/Developer: Boehringer Ingelheim and Eli Lilly & Co. billion in Q4 2022.

Sales 52

Sales Insulin FDA Approval Drugs 52